STAT

There’s little evidence abuse-deterrent opioids work. Why should we use them?

Two reasons why it's too soon to mandate the use of abuse-deterrent opioids: There's no evidence that they work, and they are 10-20 times more expensive.
The painkiller OxyContin was reformulated to deter abuse.

In the late 1990s, the pharmaceutical industry reassured physicians that, with the advent of new formulations, opioids could be safely prescribed with little risk of addiction or abuse to patients who had legitimate pain. The American Pain Society, with funding from the pharmaceutical industry, introduced its “pain as the 5th vital sign” campaign, urging physicians to assess patients’ pain and develop plans to address it. In the years that followed, prescriptions for opioids dramatically increased, at great cost to the U.S. health system and to communities across the country.

The pharmaceutical industry has proposed using so-called as an important way to address the opioid epidemic that emerged

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly’s Zepbound For Sleep Apnea, The FDA Budget, And More
Eli Lilly reported positive results for Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market.
STAT1 min read
STAT+: In Large Trial, Guardant Health’s Blood Test Detects Colon Cancer, But Less Reliably At Earliest Or Precancerous Stages
If approved, Guardant Health’s liquid biopsy is likely to be a strong new addition to colorectal cancer screening tools, particularly for patients who currently choose not to get screened.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An OptumRx Contract, 340B Dispute Resolution, And More
Cardinal Health announced its pharmaceutical distribution contracts with UnitedHealth's OptumRx unit will not be renewed after they expire in June.

Related Books & Audiobooks